Immunoexpression of epithelial membrane antigen in canine meningioma: Novel results for perspective considerations.
EMA
MUC1
dog
epithelial membrane antigen
immunohistochemistry
meningioma
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
10
05
2020
revised:
26
08
2020
accepted:
28
08
2020
pubmed:
3
9
2020
medline:
23
9
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Epithelial membrane antigen (EMA) is one of the most widely used diagnostic immunohistochemical markers for human meningioma. To date, no published study on EMA expression in formalin-fixed paraffin-embedded (FFPE) tissue samples of canine meningioma is available. Here, we describe the results of an immunohistochemical study on 25 FFPE canine meningiomas using a monoclonal anti-human EMA antibody. All meningiomas showed positive staining for EMA with cytoplasmic pattern, in nine cases associated with membranous staining. Area and intensity of staining were highly variable among cases. No clear relationships between tumour subtype/grade and area/intensity of staining were found. However, epithelial-like patterns showed a higher affinity for EMA compared to the mesenchymal one. The present study provides the basis to explore the potential diagnostic application of this marker in canine meningioma. To investigate EMA expression in other central nervous system tumours of dogs are necessary to assess the specificity of this marker.
Substances chimiques
Antibodies
0
Mucin-1
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-122Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Motta L, Mandara MT, Skerritt GC. Canine and feline intracranial meningioma: an updated review. Vet J. 2012;192:153-165.
Petersen SA, Sturges BK, Dickinson PJ, et al. Canine intraspinal meningiomas: imaging features, histopathologic classification, and long-term outcome in 34 dogs. J Vet Intern Med. 2008;22:946-953.
Song RB, Vite CH, Bradley CW, Cross JR. Postmortem evaluation of 435 cases of intracranial neoplasia in dogs and relationship of neoplasm with breed, age, and body weight. J Vet Intern Med. 2013;27:1143-1152.
Theaker JM, Gatter KC, Esiri MM, Fleming KA. Epithelial membrane antigen and cytokeratin expression by meningiomas: an immunohistological study. J Clin Pathol. 1986;39:435-439.
Higgins RJ, Bollen AW, Dickinson PJ, Sisó-Llonch S. Tumors of the central nervous system. In: Meuten DJ, ed. Tumors in Domestic Animals. 5th ed. Iowa, USA: Wiley Blackwell; 2017:864-869.
Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Marchal Bressenot A, Gauchotte G. Immunohistochemical approach to the differential diagnosis of meningiomas and their mimics. J Neuropathol Exp Neurol. 2017;76:289-298.
J a R-V, M a M, Gilbreath E, Patterson JS. Immunohistochemical detection of CD34, E-cadherin, claudin-1, glucose transporter 1, laminin, and protein gene product 9.5 in 28 canine and 8 feline meningiomas. Vet Pathol. 2010;47:725-737.
Montoliu P, Añor S, Vidal E, Pumarola M. Histological and immunohistochemical study of 30 cases of canine meningioma. J Comp Pathol. 2006;135:200-207.
Barnhart KF, Wojcieszyn J, Storts RW. Immunohistochemical staining patterns of canine meningiomas and correlation with published immunophenotypes. Vet Pathol. 2002;39:311-321.
Mauldin EA, Deehr AJ, Hertzke D, Dubielzig RR. Canine orbital meningiomas: a review of 22 cases. Vet Ophthalmol. 2000;3:11-16.
Ide T, Uchida K, Suzuki K, Kagawa Y, Nakayama H. Expression of cell adhesion molecules and doublecortin in canine anaplastic meningiomas. Vet Pathol. 2011;48:292-301.
Mandara MT, Ricci G, Rinaldi L, Sarli G, Vitellozzi G. Immunohistochemical identification and image analysis quantification of oestrogen and progesterone receptors in canine and feline meningioma. J Comp Pathol. 2002;127:214-218.
Mandara MT, Reginato A, Foiani G, et al. Papillary meningioma in the dog: a clinicopathological case series study. Res Vet Sci. 2015;100:213-219.
Foiani G, Guelfi G, Chiaradia E, et al. Somatostatin receptor 2 expression in canine meningioma. J Comp Pathol. 2019;166:59-68.
Shinada M, Kato D, Kamoto S, et al. PDPN is expressed in various types of canine tumors and its silencing induces apoptosis and cell cycle arrest in canine malignant melanoma. Cell. 2020;9(5):1136.
Sousa AM, Grandgenett PM, David L, Almeida R, Hollingsworth MA, Santos-Silva F. Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis. APMIS. 2016;124(11):913-924.
Manuali E, De Giuseppe A, Feliziani F, et al. CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res. 2012;8:86.
Ikeda H, Yoshimoto T. Immunohistochemical study of anaplastic meningioma with special reference to the phenotypic change of intermediate filament protein. Ann Diagn Pathol. 2003;7:214-222.
Schnitt SJ, Vogel H. Meningiomas. Diagnostic value of immunoperoxidase staining for epithelial membrane antigen. Am J Surg Pathol. 1986;10(9):640-649.
Shintaku M, Honda T, Sakai T. Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. Brain Tumor Pathol. 2010;27(1):23-27.
Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 2015;130(3):441-443.
Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C. The potential involvement of E-cadherin and ß-catenins in meningioma. PLos One. 2010;5:e11231.
Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1 (CD227): A multi-tasked molecule. Cell Mol Life Sci. 2015;72(23):4475-4500.
Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today. 1998;4:397-403.
Chetty R, Cooper K, Gown A, eds. Leong's Manual of Diagnostic Antibodies for Immunohistology. Cambridge: Cambridge University Press; 2016.
de Oliveira JT, Pinho SS, de Matos AJ, Hespanhol V, Reis CA, Gärtner F. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. Vet J. 2009;182:491-493.
Campos LC, Silva JO, Santos FS, et al. Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet Diagn Investig. 2015;27:531-535.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-820.
Cordell J, Richardson TC, Pulford KA, et al. Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer. 1985;52:347-354.
Doglioni C, Dell'Orto P, Coggi G, Iuzzolino P, Bontempini L, Viale G. Choroid plexus tumors. An immunohistocytochemical study with particular reference to the coexpression of intermediate filament proteins. Am J Pathol. 1987;127(3):519-529.
Bordeaux J, Welsh A, Agarwal S, et al. Antibody validation. BioTechniques. 2010;48:197-209.
Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol. 2004;2:4.
Hudson MJ, Stamp GW, Chaudhary KS, et al. Human MUC1 mucin: a potent glandular morphogen. J Pathol. 2001;194:373-383.
Johnson GC, Coates JR, Wininger F. Diagnostic immunohistochemistry of canine and feline intracalvarial tumors in the age of brain biopsies. Vet Pathol. 2014;51:146-160.
Agaimy A, Buslei R, Coras R, Rubin BP, Mentzel T. Comparative study of soft tissue perineurioma and meningioma using a five-marker immunohistochemical panel. Histopathology. 2014;65:60-70.